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Abstract 
 
We describe a new class of NO-donor hypoglycemic products obtained by joining tolbutamide, a 
typical hypoglycemic sulfonylurea, with a NO-donor moiety through a hard link. As NO-donors we 
chose either furoxan (1,2,5-oxadiazole 2-oxide) derivatives or the classical nitrooxy function. A 
preliminary biological characterization of these compounds, including stimulation of insulin release 
from cultured rat pancreatic b-cells and in vitro vasodilator and anti-aggregatory activities, is 
reported. 
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Diabetes mellitus is a metabolic disorder characterized by chronic hyperglycemia, with disorders of 
the carbohydrate, fat, and protein metabolism. It causes long-term complications in target organs, 
including retina, kidney, peripheral nerves, and the cardiovascular system. From the etiological 
standpoint, diabetes mellitus is caused by defects in the secretion and/or action of insulin. Two main 
types of diabetes are recognized: type 1 (T1DM), which is primarily due to pancreatic islet beta-cell 
autoimmune destruction, and typically causes ketoacidosis, and type 2 (T2DM), the commoner 
form of diabetes, which results from defects of insulin secretion and is almost always associated 
with the body cells’ inability to adequately respond to insulin (insulin resistance).1 Diabetes is now 
one of the most significant public health problems, due to a worldwide increase in this disease.
2
 
This increase foreshadows a rapid increase in chronic diabetic complications, including blindness, 
renal failure, peripheral neuropathy, and multiple athero-thrombotic lesions, involving coronary, 
cerebral, and peripheral arteries. There is general agreement that arterial damage is the most 
important factor involved in the high incidence of morbidity and reduced life-expectancy in diabetic 
patients. T2DM, in particular, is characterized by a complex profile of cardiovascular risk, due to 
the presence of hyperglycemia, dyslipidemia, arterial hypertension, endothelial dysfunction, and 
multiple hemostatic alterations.
3–5
 It is recognized that impaired formation and/or availability of 
endothelium-derived nitric oxide (NO, EDRF) may be a crucial factor in the development of 
cardiovascular events in diabetes mellitus.
6
 
NO is an endogenous messenger, believed to play a significant role in the maintenance of micro- 
and macro-vascular homeostasis. It inhibits platelet adherence and aggregation, decreases leukocyte 
chemotaxis, promotes endothelial regeneration and angiogenesis, reduces vascular smooth-muscle 
cell (VSMC) constriction, migration and proliferation, and enhances VSMC apoptosis.
7
 NO triggers 
a complex cascade of events in target cells, by activating soluble guanylate cyclase (sGC), which 
induces synthesis of 3,5-cyclic guanosine monophosphate (cGMP) leading to activation of the 
cGMPdependent protein kinase PKG (NO/cGMP/PKG pathway).
8
 
In T2DM, therapeutic guidelines recommend an aggressive multiple intervention policy, including 
hypoglycemic, hypotensive and anti-platelet aggregation drugs, in the setting of cardiovascular 
prevention. Thus also in diabetes, as for other complex diseases requiring the administration of 
multiple drugs, there is today great interest in the availability of hybrid drugs, known also as 
polyvalent or multifunctional drugs, which simultaneously modulate more than one target.
9,10
 In 
particular, compounds deriving from the hybridization of a hypoglycemic drug with NO-donor 
moieties would appear to be of great interest for the treatment of T2DM. Compounds of this type 
have recently been characterized, namely NO-donor pro-drugs of the hydroxylated active 
metabolite of glibenclamide, a well-known hypoglycemic agent.
11
 As a further development of our 
work on NO-donor hybrid compounds, we here describe a new class of NO-donor hypoglycemic 
products, which are not co-drugs, obtained by joining tolbutamide 1 (Chart 1), a typical 
hypoglycemic sulfonylurea, with a number of NO-donor moieties (NO-donor tolbutamides), 
through a hard link. As NO-donors, we chose either furoxan (1,2,5-oxadiazole 2-oxide) derivatives, 
in view of their remarkable ability to induce anti-aggregatory effects
12
 and vasodilation without 
inducing tolerance,
13
 or the classical nitrooxy function (ONO2). It is generally accepted that 
furoxans release NO in the presence of thiol co-factors,
14
 while nitrooxy derivatives require 
enzymatic bioactivation to do so.
15
 In order to modulate the amount of exogenous NO supplied by 
the constructs, we used either differently-substituted furoxan derivatives, or moieties containing one 
or two nitrate groups. The synthesis of these products is reported and discussed, together with a 
preliminary biological characterization, including the stimulation of insulin release from cultured rat 
pancreatic b-cells (INS-1E line) and in vitro vasodilator and anti-aggregatory activities. Since both 
inhibitory and stimulatory effects, on glucose-induced insulin secretion by INS-1E cells, have been 
ascribed to NO, the simple NO-donor substructures (see Schemes 4 and 5) present in these products 
were also tested, as controls.
16
 
Synthesis of the target products and of the intermediates used for their preparation is summarized in 
Schemes 1–3. Briefly, the intermediate mononitrate 4 was obtained by action of the 4-
hydroxybenzenesulfonamide (2) on the previously-described tosylate of 3-hydroxypropyl nitrate 3, 
in the presence of NaOH (Scheme 1). The final mononitrate 5 was prepared by treating 4 with CuCl 
and butyl isocyanate in DMF. The dinitrate target compound 8 was synthesized in a similar manner, 
starting from dinitrate 7, in turn obtained by action of iodine and AgNO3 on 6. The sulfonamide 6 is 
the product of the nucleophilic attack of the sodium salt of 2 on allyl bromide, in ethanol. 
Nucleophilic attack of 2 on 3,4-bisphenylsulfonylfuroxan (9), in the presence of Na2CO3 in DMF, 
afforded the 3-phenylsulfonyl substituted furoxan 10 in a regioselective manner (Scheme 2). The 
final furoxan 11 was obtained starting from 10, following the procedure used to prepare the nitrates 
5 and 8. The 4-bromomethyl-3-phenylfuroxan 13 was obtained by action of SOBr2 on the 
corresponding hydroxyderivative 12. The 4-bromomethylfuroxans, appropriately substituted at the 
3-position, were subjected to reaction with 2 in the presence of NaOH or Na2CO3, to give the 
intermediate solfonamides 16–18. These products were transformed into the corresponding target 
compounds (19, 20, 21) via the usual reaction with CuCl and butyl isocyanate. The general 
procedure to prepare the target compounds 5, 8, 11, 19, 20, 21 and their spectral characterization are 
reported in reference.
17
 
The simple substructures containing NO-donor nitrooxy functions 24, 26, used for control purposes, 
were obtained via the pathways outlined in Scheme 4. The mononitrate 24 was prepared under 
Mitsunobu conditions,
18
 namely by treating the adduct of Ph3P and diisopropylazodicarboxylate 
(DIAD) in THF solution with phenol 22, followed by addition of the alcohol 23. The dinitrate 26 
was synthesized by treating a mixture of silver nitrate and (allyloxy)benzene (25) with iodine in 
acetonitrile at room temperature, followed by reflux. The simple NO-donor furoxans 27–29 were 
prepared by procedures reported in Scheme 5. Furoxans 27, 28 were obtained from the related 
(bromomethyl)furoxans 13, 14 through nucleophilic displacement of bromine by sodium salt of 
phenol. Finally, the cyano substituted furoxan 29 was prepared by trifluoroacetic anhydride 
dehydration of the parent amide 28 in THF solution, in the presence of pyridine. The 
3-phenylsulfonyl substituted furoxan 30 (Chart 1) was synthesized as reported in the literature.
19
 
The ability of the NO-donor hybrids to release NO was assessed by detecting nitrite, the principal 
final product of NO oxidative metabolism, using the Griess reaction. After incubation in rat liver 
homogenate, nitrates 5, 8 generated nitrite (8 > 5). The furoxantolbutamides (11, 20, 21) produce 
nitrite when incubated with an excess of L-cysteine in buffer solution (pH = 7.4). Under these 
conditions, the NO release from compound 19 was undetectable. 
Parallel experiments, on INS-1E cells exposed to the NO-donor hybrids, showed a significant 
production of nitrite for compounds 8, 11, 19, and 21 (see Supplementary data). 
The ability of the synthesized products to supply exogenous NO to blood vessels was evaluated by 
assessing their capacity to induce relaxation of rat aorta strips pre-contracted with phenylephrine, 
following a procedure described elsewhere.
20
 Both nitrate and furoxan derivatives of tolbutamide 
were found to determine relaxation of the contracted strips in a concentration dependent manner, as 
reported for the example in Figure 1. The vasodilator potencies of the products, expressed as EC50, 
are given in Table 1. When the experiments were repeated in the presence of 
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), a well-known inhibitor of sGC, a significant 
reduction in the vasodilator effect of the products occurred (Table 1). This strongly supports the 
involvement of NO in the vasodilator action. Analysis of the data shows that the most potent 
vasodilator is the 3-phenylsulfonylfuroxan derivative 11, which is active in the nM range, followed 
in order by the 3-CN substituted compound 21 and the 3-carbamoyl analogue 20. The 3-
phenylfuroxan derivative is the least potent vasodilator of the furoxan series, having an EC50 (2.4) 
in the low M range. The potency ranking parallels the electron-withdrawing properties of 
substituents at the 3-position of the ring. This is in keeping with the hypothesis that NO release by 
the furoxan system is triggered by nucleophilic attack of a thiol cofactor at the 3-position of the 
ring.
14,21
 The nitrates also display potencies in the low M range, the di-ester 8 being somewhat 
more potent than the mono-ester 5. 
The anti-aggregatory effects of the compounds were evaluated by measuring collagen-induced 
platelet aggregation of human platelet-rich plasma (PRP), following a procedure reported 
elsewhere.
22
 The results, expressed as either IC50 or, when IC50 could not be calculated, as the 
percentage of inhibition at the maximal concentration tested (300 M), are in Table 1. Analysis of 
the data shows that the potent vasodilator hybrid furoxans 11 and 21 are also potent anti-
aggregatory agents. This finding is in agreement with the hypothesis that platelets possess the 
appropriate machinery for inducing NO release from furoxans.
12
 The involvement of NO in the 
anti-aggregatory effect is demonstrated by the substantial loss of this property when the 
experiments are carried out in the presence of ODQ. The low activity of the remaining two hybrid 
furoxans, 19 and 20, is presumably due to their lower capacity to release NO, and in the case of 20 
also to a hydrophilic–lipophilic balance that is not suitable to penetrate the platelets. The lack of 
antiaggregatory action displayed by hybrid nitric acid esters 5 and 8 is not surprising, in view of the 
established poor capacity of platelets to produce NO from nitrates.
23
 
Tolbutamide is a well-known hypoglycemic drug belonging to the class of sulfonylureas, which act 
by stimulating insulin release from pancreatic b cells, through a specific interaction with the SUR-1 
subunit of the ATP-dependent K
+
 channel, leading to the channel’s closure, beta-cell depolarization, 
opening of voltage dependent Ca
2+
 channels, increased Ca
2+
 fluxes into beta cells, and ultimately 
insulin secretion.
24
 In order to verify whether the NO-donor tolbutamide analogues described here 
retain the insulin secretagogue properties of the native drug, we studied all the products, as well as 
the corresponding simple NO-donor substructures (i.e., the two nitric esters 24, 26 and the four 
furoxans 27–30), for their ability to stimulate insulin secretion from the well-differentiated rat 
pancreatic  cell line INS-1E, which releases insulin in a glucose-regulated manner.25,26 INS-1E 
cells were incubated in KRB/Hepes buffer in the presence of various glucose concentrations and 
200 M of product; the results are in Figures 2, 3 and 4. Tolbutamide, which was tested as a 
reference compound, enhanced insulin release by approximately 2.5 times versus control cells (Fig. 
2). Under the same conditions, all synthesized hybrid products likewise significantly increased 
insulin release versus 2 mM glucose, although to different extents. Some products increased insulin 
secretion as much as tolbutamide (namely compounds 8, 19, 21) or to a greater extent (compound 
11), whereas others (compounds 5 and 20), were less effective than tolbutamide. In parallel 
experiments we also tested some compounds at a concentration of 100 M which, in most cases 
significantly increased insulin secretion with respect to the control, but to a lesser extent than the 
higher concentration (see Supplementary data). 
As the simple NO-donor moieties (24, 26–30), tested at 200 M under the same experimental 
conditions, did not significantly increase insulin release (Fig. 3), it is reasonable to assume that the 
role of NO, if any, on glucose-induced insulin secretion from INS-1E cells by the NO-tolbutamides, 
must be negligible. 
The hybrid NO-donor compounds showing insulin-secretory effects similar to or higher than that of 
tolbutamide, at 2 mM glucose, were also challenged at various glucose concentrations. As shown in 
Figure 4, the results substantially confirm that all NO releasing compounds (i.e., 8, 11, 19, 21) 
exhibit patterns of insulin secretion similar to that of tolbutamide, characterized by an increasing 
effect depending on glucose concentrations up to 4 mM. It should be pointed out that when INS-1E 
cells are exposed to glucose concentrations higher than 4 mM (e.g., 5.6 or 11 mM), tolbutamide as 
well as its NO-donor derivatives are unable to further increase glucose-stimulated insulin secretion 
(see Supplementary data). 
Thus, in most cases, the structural modifications induced, with the goal of obtaining tolbutamide 
analogues endowed with NO releasing properties, do not hamper the compounds’ effectiveness in 
terms of insulin secretion, although there may be some change with respect to tolbutamide. 
One problem with hybrid drugs, in which the stoichiometry between the two pharmacophores 
present is necessarily 1:1, is that these pharmacophores must display their biological activities in the 
same concentration range. This is a difficult goal to achieve, and success can only be evaluated 
through in vivo experiments. The results of this in vitro study indicate that the most interesting 
products for in vivo testing are compounds 5, 19, 20 in which the tolbutamide pharmacophore is 
combined with substructures endowed with low/moderate NO dependent activity. Compounds 11 
and 21 are too potent NO-donors to give rise to a balanced hybrid drug in vivo; however, a 
dedicated study will be necessary to confirm this, in view of the probable different pharmacokinetic 
properties of the products. 
In conclusion, we successfully obtained new hybrid compounds, which are not co-drugs, that 
combine the insulin secretagogue properties of tolbutamide with the ability to restore endothelial 
function, due to their ability to activate the NO/cGMP/PKG pathway. The products were obtained 
by combining tolbutamide with NO-donor nitrooxy and furoxan moieties endowed with different 
NO-releasing capabilities. Compounds 5, 19, and 20, in which the tolbutamide pharmacophore is 
combined with substructures that display low or moderate NO-dependent vasodilator activity, 
emerged as models for which additional in vivo studies would be worthwhile, as they are potentially 
useful as drugs to treat diabetes. 
 
Supplementary data 
 
Supplementary data associated with this article can be found, in the online version, at 
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calculated by nonlinear regression analysis; otherwise, percent inhibition at the maximal 
concentration tested (300 M) is reported. 
23. Weber, A. A.; Neuhaus, T.; Seul, C.; Dusing, R.; Schror, K.; Sachinidis, A.; Vetter, H. Eur. J. 
Pharmacol. 1996, 309, 209. 
24. Proks, P.; Reimann, F.; Gribble, F.; Ashcroft, F. Diabetes 2002, 51(Suppl 3), S368. 
25. Merglen, A.; Theander, S.; Rubi, B.; Chaffard, G.; Wollheim, C. B.; Maechler, P. 
Endocrinology 2004, 145, 667. 
26. Cell culture: INS-1E cells were cultured in a humidified atmosphere containing 5% CO2 in 
complete medium composed of RPMI 1640 supplemented with 10% heat-inactivated fetal calf 
serum, 1 mM sodium pyruvate, 50 M 2-mercaptoethanol, 2 mM glutamine, 10 mM HEPES, 100 
U/ml penicillin and 100 lg/ml streptomycin. The maintenance culture was passaged once a week 
by gentle trypsinisation. Insulin secretion: The secretory response to glucose and other 
secretagogues was tested in INS-1E cells between passages 54 and 65. Cells were seeded in 24-well 
plates at a density of 4 x 10
4
 cells/cm
2
 in RPMI medium. After 48 h, medium was removed and 
cells were pre-incubated for 1 h at 37 °C in Krebs-Ringer bicarbonate buffer with HEPES (KRBH) 
containing 0.5% bovine serum albumin (BSA, fraction V, Sigma) and basal glucose concentrations 
(1 or 2 mM, according to the protocol). At the end of the pre-incubation time, cells were washed 
and then incubated for 1 h at 37 °C in 1 mL fresh KRBH buffer containing 0.5% BSA and suitable 
glucose concentrations, in the presence or absence of tolbutamide and its derivatives, used at 
concentrations of 100 or 200 M. At the end of the incubation, the buffer was collected for insulin 
determination. Finally, 1 mL of cold acidified ethanol (150:47:3, v/v, absolute 
ethanol/H2O/concentrated HCl) was added to the cells and left for 24 h in order to extract their 
insulin content. Insulin was measured in the buffer and in the acid-ethanol extract by 
radioimmunoassay according to Herbert et al. (Herbert V.; Lau K. S.; Gottlied C.W.; Bleicher S. J. 
Coated charcoal immunoassay of insulin. J. Clin. Endocrinol. 1965, 25, 1375), using rat insulin as a 
standard. The sensitivity and the coefficient of variation of the radioimmunoassay were as follows: 
detection limit 0.13 ng/mL, intra-assay variation 3.3%, inter-assay variation 10.5%. 
  
Chart 1. Structure of Tolbutamide (1) and of compound 30. 
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Scheme 1. (a) Tosylpropylnitrate (3), NaOH, EtOH; (b) CuCl, butylisocyanate, DMF; (c) 
allylbromide, NaOH, EtOH; (d) I2, AgNO3, CH3CN, rt then reflux. 
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Scheme 2. (a) Na2CO3, DMF; (b) CuCl, butylisocyanate, DMF. 
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Scheme 3. (a) SOBr2, DMF; (b) NaOH, EtOH for R = Ph, CONH2; Na2CO3, DMF for R = CN; (c) 
CuCl, butylisocyanate, DMF. 
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Scheme 4. (a) Ph3P, DIAD, THF; (b) I2, AgNO3, CH3CN, rt then reflux. 
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Scheme 5. (a) Na, THF, 0 °C to rt; (b) (CF3CO)2O, Py, THF, 0 °C to rt. 
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Figure 1. Concentration response curves for vasodilator activity of compound 21 in the absence and 
in the presence of ODQ. 
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Figure 2. Insulin release from INS-1E cell line exposed to 1, 5, 8, 11, 19, 20, and 21 at 200 M 
concentration in the presence of 2 mM glucose (control). Data are mean values ± SEM of 8–12 
determinations for tolbutamide derivatives and 20–24 determinations for control and 1.*p <0.05 at 
least versus control; 
§
 p<0.05 at least versus 1. 
  
Figure 3. Insulin release from INS-1E cell line exposed to 1, 24, 26, 27, 28, 29, and 30 at 200 M 
concentration in the presence of 2 mM glucose (control). Data are mean values ± SEM of 8–12 
determinations for NO-donor derivatives and 20–24 determinations for (control) and 1.*p <0.05 at 
least versus (control). 
  
Figure 4. Insulin release from INS-1E cell line exposed to 1, 8, 11, 19, 21 at 200 M concentration 
in the presence of different glucose concentrations (G1, G2, G4). Data are mean values ± SEM of at 
least 5 determinations for tolbutamide derivatives and 15–20 determinations for glucose alone and 
for 1. *p <0.05 at least versus corresponding glucose concentrations. 
  
Table 1 
Anti-aggregatory and vasodilator activity of compounds 1, 5, 8, 11, 19, 20, 21. 
 
 
Compound Antiaggregatory activity Vasodilator activity 
 
IC50 (M) (CL 95%) 
[+ 50 M ODQ] 
% inhibition ± SEM at 300 M a) 
EC50 (M) ± SEM 
[+ 1 M ODQ] 
1  6.4 ± 4.3 Inactive 
5  1.1 ± 1.1 
1.6 ± 0.2 
b) 
8  5.6 ± 4.5 
0.90 ± 0.10 
[61 ± 16] 
11 
10 (8.9-12) 
[34 (32-37)] 
 
0.0024 ± 0.0001 
[0.22 ± 0.04] 
10 
26 (22-30) 
[209 (188-232)] 
 
0.010 ± 0.001 
[0.90 ± 0.06] 
19  13 ± 4 
2.4 ± 0.2 
b)
 
20  5.2 ± 1.0 
0.74 ± 0.09 
[57 ± 1] 
21 
26 (22-30) 
[209 (188-232)] 
 
0.010 ± 0.001 
[0.90 ± 0.06] 
